Rheumatology (Oxford, England) · 2025
Axial psoriatic arthritis in patients not fulfilling the back pain entry features of the ASAS Classification Criteria for Axial Spondyloarthritis: findings from the ATTRACT Study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Paci Valentino, Proft Fabian, Agostinelli Alice, Sordillo Raffaella, Cimaroli Ilaria, Giannoni Melania, Campanati Anna, Carotti Marina, Sessa Francesco, Fiorini Federico, Ciferri Monia, Giovagnoni Andrea, Polonara Gabriele, Benfaremo Devis, Foti Rosario, Moroncini Gianluca, Lubrano Ennio, Poddubnyy Denis, Luchetti Gentiloni Michele Maria
Аннотация
OBJECTIVE: Application of the ASAS classification criteria for axSpA in classifying axPsA is a topic of debate. In this study, we aimed to determine the prevalence of axPsA in patients with psoriasis and back pain who do not meet the entry pain features of the ASAS classification criteria.
METHODS: Patients reporting late-onset back pain (LoBP, after the age of 45) or non-chronic back pain (NcBP, lasting less than months) in the DCS screening tool were included in a group termed 'non-ASAS back pain' (non-ASAS/BP). They underwent clinical/instrumental assessment aimed at axPsA diagnosis and were compared with those patients fulfilling both of two ASAS entry pain features at the screening (ASAS/BP).
RESULTS: After rheumatological evaluation, 50/265 (18.8%) patients, 34/50 (68%) LoBP and 16/50 (32%) NcBP, were categorized as the non-ASAS/BP group. In comparison with ASAS/BP patients, the mean age was higher, and the prevalence of IBP was lower. Clinical disease activity was similar between the two groups. AxPsA was confirmed in 6/50 (12%) non-ASAS/BP patients, which is a lower incidence than in the ASAS/BP group (29.0%). Finally, non-ASAS/BP axPsA patients showed a similar proportion of inflammatory and post-inflammatory radiographic and/or MRI changes as shown in ASAS/BP axPsA patients.
CONCLUSION: This study demonstrates that among psoriatic patients who experience late-onset or non-chronic back pain, thereby not fulfilling ASAS entry pain features, a considerable proportion may be affected by active axPsA.
METHODS: Patients reporting late-onset back pain (LoBP, after the age of 45) or non-chronic back pain (NcBP, lasting less than months) in the DCS screening tool were included in a group termed 'non-ASAS back pain' (non-ASAS/BP). They underwent clinical/instrumental assessment aimed at axPsA diagnosis and were compared with those patients fulfilling both of two ASAS entry pain features at the screening (ASAS/BP).
RESULTS: After rheumatological evaluation, 50/265 (18.8%) patients, 34/50 (68%) LoBP and 16/50 (32%) NcBP, were categorized as the non-ASAS/BP group. In comparison with ASAS/BP patients, the mean age was higher, and the prevalence of IBP was lower. Clinical disease activity was similar between the two groups. AxPsA was confirmed in 6/50 (12%) non-ASAS/BP patients, which is a lower incidence than in the ASAS/BP group (29.0%). Finally, non-ASAS/BP axPsA patients showed a similar proportion of inflammatory and post-inflammatory radiographic and/or MRI changes as shown in ASAS/BP axPsA patients.
CONCLUSION: This study demonstrates that among psoriatic patients who experience late-onset or non-chronic back pain, thereby not fulfilling ASAS entry pain features, a considerable proportion may be affected by active axPsA.